Transactions classified within the Biotechnology & Medical Research sub-sector. Sectors follow a structured hierarchy so filters and comparable sets stay reproducible.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Merida Biosciences | Eli Lilly | Bio Therapeutic Drugs | $2,880M | n/m | |
| Personalis | Tempus AI | Biotechnology & Medical Research (NEC) | $361M – $489M | n/m | |
| Becton Dickinson’s Biosciences & Diagnostics Unit | Waters | Bio Diagnostics & Testing | $15,000M | 16× – 21× | |
| Early Phase Services division of Worldwide Clinical Trials | Fortrea | Biotechnology & Medical Research (NEC) | $45.0M | 4× – 5× | |
| Worldwide Clinical Trials Early Phase Services division | Fortrea | Biotechnology & Medical Research (NEC) | $45.0M | 6× – 8× | |
| Nuvalent | GSK | Bio Therapeutic Drugs | $10,600M | 38× – 40× | |
| Alesta Therapeutics | BioMarin Pharmaceutical Inc. | Bio Therapeutic Drugs | $85.0M – $115M | n/m | |
| Neurona Therapeutics | UCB | Bio Therapeutic Drugs | $47.2M – $63.8M | n/m | |
| Merida Biosciences | Eli Lilly and Co. | Bio Therapeutic Drugs | $2,875M | n/m | |
| Thermo Fisher Scientific microbiology business | Astorg | Bio Diagnostics & Testing | $1,075M | 7× – 9× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.